An observational study in Systemic Sclerosis, sponsored by Hôpital Européen Marseille. Recruiting at 1 site in France. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-25.
Sponsored by Hôpital Européen Marseille · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 132 studies in Scleroderma, Systemic with a site in France — 44 open to participants now, 48 under way, 7 of them phase 3. Scleroderma, Systemic · France.
Among the 132 studies in Scleroderma, Systemic with a site in France, this one is the 38th largest by planned enrollment of the 50 observational ones that give a count, is one of 4 that started in 2019, is one of 51 observational ones, reaches primary completion later than 11 of the 47 other live ones, and was the 63rd registered.
614 studies on the registry are indexed under Scleroderma, Systemic; 222 are open to participants now.
Browse Scleroderma, Systemic studies →44 of the 132 studies in Scleroderma, Systemic with a site in France are open now. Recruiting first, the newest first:
University Hospital, Montpellier · Sites in France
Ages 18–85 · Healthy volunteers
AstraZeneca · Sites in France, United States, Argentina and 32 more countries
Ages 5–80
Boehringer Ingelheim · Sites in France, United States, Argentina and 42 more countries
Ages 18+
University Hospital, Montpellier · Sites in France
Ages 18+ · Healthy volunteers
University Hospital, Montpellier · Sites in France
Ages 18–64
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 147 Scleroderma, Systemic studies recruiting now, 85 (58%) set no upper age limit and 49 (33%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
132 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 28 · Phase 3 15
First in 2001; this study’s year is marked. 4 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 100 across 145 observational studies indexed under Scleroderma, Systemic.
Median enrollment 75 across the 81 interventional studies, 150 across the 50 observational. Of the 71 that completed or were terminated, 8 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 132 have an industry lead sponsor. The 10 most frequent:
Hôpital Européen Marseille is the lead sponsor of 30 studies on the registry; 8 are open to participants now.
Hôpital Européen Marseille has 1 study filed under Scleroderma, Systemic — fewer than ten, so there is no comparison to draw.
7 of the studies in Scleroderma, Systemic with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05925803Phase 3AstraZenecaDetermine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY) | 2027-01-06 |
| NCT06655155argenxA Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis | 2027-03 |
| NCT04356755University Hospital, ToulouseSubcutaneous Injections of ASC to Heal Digital Ulcers in Patients With Scleroderma. | 2027-03 |
| NCT07888842Assistance Publique - Hôpitaux de ParisA Clinical Study on Systemic Sclerosis and the Validation of French-language Questionnaires Assessing Disability, Quality of Life, and Disease Status. | 2027-05 |
| NCT07543679Centre Hospitalier Universitaire de Saint EtienneObjective Assessment of Skin Damage Using ADHELASKIN in Patients With Systemic Sclerosis | 2027-05-01 |
Add all 7 to your calendar (.ics) → With an account.
Among the 132 studies in Scleroderma, Systemic with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Today, the study of gut microbiota has taken a prominent place in several fields of medical research. Numerous experimental data in humans and animals suggest that an imbalance in the composition of the microbiota could contribute to the pathophysiology of systemic autoimmune diseases such as Systemic Sclerosis (SCS). A future exploration of the microbiota, a source of diagnostic and/or prognostic biomarkers, may be very useful for tomorrow's medicine by proposing therapeutic interventions based on the correction of possible imbalances in the intestinal flora. Studies of the human gut microbiota in patients with ScS are limited to low-impact investigations, due to the lack of data on the clinical and biological characterization of the patients studied, and to the absence of longitudinal studies in the same patient. For this reason, we are interested in exploring the intestinal microbiota of ScS patients in a comprehensive and longitudinal way.
This is an explorative, prospective, monocentric open-label study qualified as interventional researches at minimal risks and constraints (called in French RIPH, category 2).
This is a study of the gut microbiota and its characteristics in ScS patients, compared to control subjects (without ScS or other chronic diseases), matched on age and sex.
Participants provided two stool samples: one collected the day of inclusion and a second, six months later.
In parallel with the microbiota analysis, a clinical (digestive and extra digestive signs, severity) and biological characterization of the ScS will be carried out by the team of internists. This medical evaluation will be completed by an interview with a dietician to inform about the participant's eating habits, and any changes in the 7 days preceding the stool collection.
Microbial profiles will be obtained from the sequencing data using the specialized tools DADA2 and Kraken.
The search of characteristic signature of ScS will be performed by comparing ScS patients and healthy controls using a discriminant linear analysis (LDA) using the specialized tool LEfSe Main objective is to identify, through longitudinal follow-up, significant differences in the composition of the intestinal microbiota of ScS patients and healthy control subjects (matched on age and sex) in order to define a microbial signature specific to the ScS.
Secondary objectives are to study the stability over time of the identified microbial signatures, and to determine a correlation between the composition of the microbiota obtained in the ScS patient and the severity of his symptoms (diffuse skin disease, pulmonary interstitial disease, digestive disease...)
Patients with ScS according to ACR criteria,and healthy volunteers without diagnosis of ScS or any other chronic disease
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For ScS patients:
For control subjects:
Exclusion Criteria:
1. Persons with severe anemia ( \< 7 g/dL). 2. Persons who cannot read French. 3. For control subjects: Persons with a particular symptom (as an example of digestive disorders), or under long-term treatment related to another pathology.
4. Persons treated with antibiotics, probiotics, prebiotics or any other treatment that may disrupt the gut microbiota within two months before stool sampling.
5. Persons referred to the article L1121-5 to 1121-8 of the Public health code, namely :
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will provide two stool samples: one collected the day of inclusion and a second, six months later
Other: stool sampling
Healthy subjects will provide one stool sample at inclusion.
Other: stool sampling
Participants will provide two stool samples: one collected the day of inclusion and a second, six months later
Differences on gut microbiota composition (bacterial populations) of ScS overtime, at different taxonomic levels (from phyla to species if technique allows) versus healthy controls.
The patient participation at the study will last 7 months, but healthy volunteers will provide stool sample only once at study entry and won't be followed after that.
Time frame: 7 months
Plan to share: Undecided
No publications or documents are linked to this record.
Started Oct 2019 (actual). Primary completion is estimated for Jun 2026, 79 months after the start.
Of 59 non-industry observational studies under Scleroderma, Systemic, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 80. This study's planned 79 months is above that.
Counting every sponsor, half of 61 studies reached it within 44 months; a quarter within 17 and three quarters within 80.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hôpital Européen Marseille